FDA Grants Full Approval to Travere Therapeutics' FILSPARI for IgA Nephropathy, Stock Rises 5.7%

Sep 6, 2024, 01:22 PM

The FDA has granted full approval to Travere Therapeutics' drug FILSPARI (sparsentan), marking it as the only non-immunosuppressive treatment that significantly slows kidney function decline in patients with IgA nephropathy (IgAN). This approval follows a conversion from an accelerated approval and comes with an expanded label. The decision has positively impacted Travere's stock, which saw a 5.7% increase in pre-market trading. The approval is expected to intensify competition with Novartis and Calliditas in the kidney disease treatment market. Ligand Partner is also associated with this approval.